Who Buys Amlodipine from India — 1862 Importers Behind a $11.5B Market

The importation of Amlodipine from India involves various buyer segments, each with distinct purchasing behaviors:

• Distributors: Entities like B Logistik GmbH (Germany) and NextPharma Logistics GmbH (Germany) function as intermediaries, procuring large volumes of Amlodipine to supply to pharmacies, hospitals, and other healthcare providers. Their purchasing patterns are characterized by bulk orders to achieve economies of scale and ensure consistent supply chains.

• Pharmaceutical Companies: Companies such as Unichem Pharmaceuticals (USA) Inc., Mylan Hungary Kft, and Cipla USA Inc. import Amlodipine for direct distribution or further manufacturing. Their procurement is driven by market demand forecasts and regulatory approvals, often involving substantial quantities to meet production and distribution needs.

• Contract Manufacturers: Entities like Ascend Laboratories LLC (United States) and Mylan Pharmaceuticals Inc. (United States) may import Amlodipine as an active pharmaceutical ingredient (API) for formulation into finished dosage forms. Their purchasing behavior is aligned with production schedules and contractual obligations, necessitating reliable and timely deliveries.

Each segment's procurement strategies are influenced by factors such as market demand, regulatory compliance, and supply chain logistics, ensuring the availability of Amlodipine to end-users.

The importation of Amlodipine into the top five importing countries involves specific regulatory processes:

• Germany:
• Regulatory Authority: Federal Institute for Drugs and Medical Devices (BfArM).
• Import Registration Process: Requires submission of a marketing authorization application, including quality, safety, and efficacy data.
• Estimated Timeline: Approximately 7 to 12 months, depending on the completeness of the application.
• Import Tariff/Duty: Pharmaceutical products under HS Code 30049072 are generally exempt from import duties within the European Union.

• United States:
• Regulatory Authority: U.S. Food and Drug Administration (FDA).
• Import Registration Process: Requires an Abbreviated New Drug Application (ANDA) for generic drugs, demonstrating bioequivalence to the reference listed drug.
• Estimated Timeline: Typically 10 to 12 months, subject to FDA review processes.
• Import Tariff/Duty: Pharmaceuticals under HS Code 30049072 are generally duty-free.

• Hungary:
• Regulatory Authority: National Institute of Pharmacy and Nutrition (OGYÉI).
• Import Registration Process: Submission of a marketing authorization application, including comprehensive documentation on the product's quality, safety, and efficacy.
• Estimated Timeline: Approximately 6 to 12 months, depending on the application specifics.
• Import Tariff/Duty: As an EU member state, Hungary generally applies a 0% import duty on pharmaceutical products under HS Code 30049072.

• Netherlands:
• Regulatory Authority: Medicines Evaluation Board (CBG-MEB).
• Import Registration Process: Requires a marketing authorization application, including detailed product information and compliance with EU regulations.
• Estimated Timeline: Around 7 to 12 months, subject to regulatory review.
• Import Tariff/Duty: Pharmaceuticals under HS Code 30049072 are typically exempt from import duties within the EU.

• South Africa:
• Regulatory Authority: South African Health Products Regulatory Authority (SAHPRA).
• Import Registration Process: Submission of a medicine registration application, including data on quality, safety, and efficacy.
• Estimated Timeline: Approximately 12 to 24 months, depending on the complexity of the application.
• Import Tariff/Duty: Pharmaceutical products under HS Code 30049072 are generally subject to a 0% import duty.

These regulatory frameworks ensure that imported Amlodipine meets the respective countries' standards for safety, efficacy, and quality.

The demand for Amlodipine, a calcium channel blocker used primarily to treat hypertension and angina, is driven by several factors:

• Disease Prevalence: Hypertension is a leading risk factor for cardiovascular diseases globally. The World Health Organization (WHO) reports that cardiovascular diseases account for approximately 31% of all global deaths, with hypertension being a significant contributor.

• Government Healthcare Programs: Many countries have implemented national health initiatives targeting non-communicable diseases. For instance, India's Hypertension Control Initiative emphasizes the inclusion of Amlodipine in treatment protocols to manage high blood pressure effectively.

• Universal Health Coverage Expansion: Efforts to achieve universal health coverage have led to increased access to essential medicines. Countries expanding their healthcare coverage often prioritize the availability of cost-effective treatments like Amlodipine to manage prevalent conditions such as hypertension.

• WHO Essential Medicines List Procurement: Amlodipine's inclusion in the WHO Essential Medicines List underscores its importance in basic healthcare systems. This designation encourages countries to procure and provide Amlodipine as part of their standard treatment regimens.

• Tender-Based Purchasing: Many governments and international organizations utilize tendering processes to procure pharmaceuticals, ensuring competitive pricing and consistent supply. This approach is particularly prevalent in low- and middle-income countries, facilitating the widespread availability of essential medicines like Amlodipine.

With 1,862 buyers across 159 countries, the global market for Amlodipine reflects its critical role in managing cardiovascular health, presenting ongoing opportunities for suppliers to meet this sustained demand.

The importation of Amlodipine from India involves various buyer segments, each with distinct purchasing behaviors:

• Distributors: Entities like B Logistik GmbH (Germany) and NextPharma Logistics GmbH (Germany) function as intermediaries, procuring large volumes of Amlodipine to supply to pharmacies, hospitals, and other healthcare providers. Their purchasing patterns are characterized by bulk orders to achieve economies of scale and ensure consistent supply chains.

• Pharmaceutical Companies: Companies such as Unichem Pharmaceuticals (USA) Inc., Mylan Hungary Kft, and Cipla USA Inc. import Amlodipine for direct distribution or further manufacturing. Their procurement is driven by market demand forecasts and regulatory approvals, often involving substantial quantities to meet production and distribution needs.

• Contract Manufacturers: Entities like Ascend Laboratories LLC (United States) and Mylan Pharmaceuticals Inc. (United States) may import Amlodipine as an active pharmaceutical ingredient (API) for formulation into finished dosage forms. Their purchasing behavior is aligned with production schedules and contractual obligations, necessitating reliable and timely deliveries.

Each segment's procurement strategies are influenced by factors such as market demand, regulatory compliance, and supply chain logistics, ensuring the availability of Amlodipine to end-users.

The importation of Amlodipine into the top five importing countries involves specific regulatory processes:

• Germany:
• Regulatory Authority: Federal Institute for Drugs and Medical Devices (BfArM).
• Import Registration Process: Requires submission of a marketing authorization application, including quality, safety, and efficacy data.
• Estimated Timeline: Approximately 7 to 12 months, depending on the completeness of the application.
• Import Tariff/Duty: Pharmaceutical products under HS Code 30049072 are generally exempt from import duties within the European Union.

• United States:
• Regulatory Authority: U.S. Food and Drug Administration (FDA).
• Import Registration Process: Requires an Abbreviated New Drug Application (ANDA) for generic drugs, demonstrating bioequivalence to the reference listed drug.
• Estimated Timeline: Typically 10 to 12 months, subject to FDA review processes.
• Import Tariff/Duty: Pharmaceuticals under HS Code 30049072 are generally duty-free.

• Hungary:
• Regulatory Authority: National Institute of Pharmacy and Nutrition (OGYÉI).
• Import Registration Process: Submission of a marketing authorization application, including comprehensive documentation on the product's quality, safety, and efficacy.
• Estimated Timeline: Approximately 6 to 12 months, depending on the application specifics.
• Import Tariff/Duty: As an EU member state, Hungary generally applies a 0% import duty on pharmaceutical products under HS Code 30049072.

• Netherlands:
• Regulatory Authority: Medicines Evaluation Board (CBG-MEB).
• Import Registration Process: Requires a marketing authorization application, including detailed product information and compliance with EU regulations.
• Estimated Timeline: Around 7 to 12 months, subject to regulatory review.
• Import Tariff/Duty: Pharmaceuticals under HS Code 30049072 are typically exempt from import duties within the EU.

• South Africa:
• Regulatory Authority: South African Health Products Regulatory Authority (SAHPRA).
• Import Registration Process: Submission of a medicine registration application, including data on quality, safety, and efficacy.
• Estimated Timeline: Approximately 12 to 24 months, depending on the complexity of the application.
• Import Tariff/Duty: Pharmaceutical products under HS Code 30049072 are generally subject to a 0% import duty.

These regulatory frameworks ensure that imported Amlodipine meets the respective countries' standards for safety, efficacy, and quality.

The demand for Amlodipine, a calcium channel blocker used primarily to treat hypertension and angina, is driven by several factors:

• Disease Prevalence: Hypertension is a leading risk factor for cardiovascular diseases globally. The World Health Organization (WHO) reports that cardiovascular diseases account for approximately 31% of all global deaths, with hypertension being a significant contributor.

• Government Healthcare Programs: Many countries have implemented national health initiatives targeting non-communicable diseases. For instance, India's Hypertension Control Initiative emphasizes the inclusion of Amlodipine in treatment protocols to manage high blood pressure effectively.

• Universal Health Coverage Expansion: Efforts to achieve universal health coverage have led to increased access to essential medicines. Countries expanding their healthcare coverage often prioritize the availability of cost-effective treatments like Amlodipine to manage prevalent conditions such as hypertension.

• WHO Essential Medicines List Procurement: Amlodipine's inclusion in the WHO Essential Medicines List underscores its importance in basic healthcare systems. This designation encourages countries to procure and provide Amlodipine as part of their standard treatment regimens.

• Tender-Based Purchasing: Many governments and international organizations utilize tendering processes to procure pharmaceuticals, ensuring competitive pricing and consistent supply. This approach is particularly prevalent in low- and middle-income countries, facilitating the widespread availability of essential medicines like Amlodipine.

With 1,862 buyers across 159 countries, the global market for Amlodipine reflects its critical role in managing cardiovascular health, presenting ongoing opportunities for suppliers to meet this sustained demand.